Our innovation

Transforming the world of diabetes management

For 30 years, Medtronic has led the technology revolution in diabetes care. This history vividly reflects our dedication and ongoing vision to develop an "artificial pancreas".


  • Medtronic’s commitment to transforming the world of diabetes management

Innovation Table

In 1983, we pioneered the idea of continuous insulin delivery, introducing our first insulin pump as the most innovative way to deliver insulin and help normalize glucose control for people with diabetes.
Since that time, Medtronic has remained the market leader, earning a reputation for excellence in insulin pump therapy, continuous glucose monitoring and data management.

  • We were the first to launch continuous glucose monitoring products in the market and the only to offer an FDA approved device for professionals.
  • We are working towards delivering the first artificial pancreas onto the market within the next few years.
  • We are the first introducing the features of MiniMed® 640G Integrated System which can guide towards better control1 and providing personalised convenience for easier daily management of diabetes.

We are committed to refining our support services and tools to build our patients' trust and confidence. With our advanced insulin pump therapy combined with our continuous glucose monitoring and data management products we deliver state-of-the-art diabetes management. A solution for people living with Type 1 diabetes today and in the future.



At Medtronic, our number one priority is the creation of an artificial pancreas – or a “closed-loop system” – which monitors glucose levels 24/7 and automatically delivers exactly the right amount of insulin.

First with the MiniMed® Veo and now with the MiniMed® 640G Integrated System (features innovative technology to more closely mimic the way a healthy pancreas delivers basal insulin to the body and helps achieve better control) we are almost there. Our scientists are now focused on developing a way to regulate insulin delivery without any user intervention whatsoever.

When complete, we’re confident that the closed-loop system will transform the lives of millions of people with diabetes worldwide.


  • 1 Compared to multiple daily injections, according to the STAR 3 clinical study: Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320.


The content and all information provided on this website is for your informational use only and is not intended to be a substitute for professional medical advice, diagnosis or treatment in any manner. The patient stories provided are experiences specific to a particular patient. Responses to a treatment may vary from patient to patient. Always talk with your physician about diagnosis and treatment information and ensure that you understand and carefully follow that information.

© 2016 Medtronic International Trading Sarl™. All Rights Reserved. No part of this website may be reproduced or utilized in any form or by any means without permission from Medtronic International Trading Sarl. MiniMed, Bolus Wizard, SMARTGUARD, Guardian, Enlite and CareLink are trademarks of Medtronic, Inc. and its subsidiaries. CONTOUR is a trademark of Bayer Healthcare LLC.